31 August 2023
EMA/COMP/336655/2023
Human Medicines Division

Committee for Orphan Medicinal Products (COMP)

Draft agenda for the meeting on 05-07 September 2023

Chair: Violeta Stoyanova-Beninska – Vice-Chair: Armando Magrelli

05 September 2023, 08:30-19:30, virtual meeting

06 September 2023, 08:30-19:30, virtual meeting

07 September 2023, 08:30-18:00, virtual meeting

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the COMP meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for COMP members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000
An agency of the European Union

Table of contents

1. Introduction 5

1.1. Welcome and declarations of interest of members and experts 5

1.2. Adoption of agenda 5

1.3. Adoption of the minutes 5

2. Applications for orphan medicinal product designation 5

2.1. For opinion 5

2.1.1. - EMA/OD/0000142116 5

2.1.2. - EMA/OD/0000140986 5

2.1.3. - EMA/OD/0000124476 5

2.1.4. - EMA/OD/0000128649 5

2.1.5. - EMA/OD/0000135016 5

2.1.6. - EMA/OD/0000122901 6

2.1.7. - EMA/OD/0000140879 6

2.1.8. - EMA/OD/0000140620 6

2.1.9. - EMA/OD/0000133480 6

2.1.10. - EMA/OD/0000138974 6

2.1.11. - EMA/OD/0000139967 6

2.1.12. - EMA/OD/0000141035 6

2.1.13. - EMA/OD/0000138272 6

2.1.14. - EMA/OD/0000137651 7

2.2. For discussion / preparation for an opinion 7

2.2.1. - EMA/OD/0000128462 7

2.2.2. - EMA/OD/0000128771 7

2.2.3. - EMA/OD/0000131662 7

2.2.4. - EMA/OD/0000135459 7

2.2.5. - EMA/OD/0000137539 7

2.2.6. - EMA/OD/0000139099 7

2.2.7. - EMA/OD/0000139511 7

2.2.8. - EMA/OD/0000140934 7

2.2.9. - EMA/OD/0000142438 8

2.2.10. - EMA/OD/0000142531 8

2.2.11. - EMA/OD/0000143040 8

2.2.12. - EMA/OD/0000143251 8

2.2.13. - EMA/OD/0000143825 8

2.2.14. - EMA/OD/0000143999 8

2.2.15. - EMA/OD/0000144104 8

2.2.16. - EMA/OD/0000144182 8
2.2.17. - EMA/OD/0000144198 8
2.2.18. - EMA/OD/0000144261 9
2.3. Revision of the COMP opinions 9
2.4. Amendment of existing orphan designations 9
2.5. Appeal 9
2.6. Nominations 9
2.6.1. New applications for orphan medicinal product designation - Appointment of COMP rapporteurs 9
2.7. Evaluation on-going 9
3. Requests for protocol assistance with significant benefit question 9
3.1. Ongoing procedures 9
3.1.1. - 9
3.1.2. - 9
4. Review of orphan designation for orphan medicinal products at time of initial marketing authorisation 10
4.1. Orphan designated products for which CHMP opinions have been adopted 10
4.2. Orphan designated products for discussion prior to adoption of CHMP opinion 10
4.2.1. - quizartinib - EMEA/H/C/005910/0000, EU/3/09/622, EMA/OD/0000134652 10
4.2.2. - zilucoplan - EMEA/H/C/005450/0000, EU/3/22/2650, EMA/OD/0000120845 10
4.2.3. – teriparatide - EMEA/H/C/005934, EU/3/20/2350, EMA/OD/0000140073 10
4.3. Appeal 10
4.3.1. Jaypirca - pirtobrutinib - EMEA/H/C/005863, EU/3/21/2450. 10
4.4. On-going procedures 10
4.5. Orphan Maintenance Reports 10
5. Review of orphan designation for authorised orphan medicinal products at time marketing authorisation extension 11
5.1. After adoption of CHMP opinion 11
5.2. Prior to adoption of CHMP opinion 11
5.2.1. Adcetris - brentuximab vedotin - EMEA/H/C/002455/II/0109, EU/3/08/595, EMA/OD/0000146788 11
5.2.2. Adcetris - brentuximab vedotin - EMEA/H/C/002455/II/0107, EU/3/08/596, EMA/OD/0000136638 11
5.3. Appeal 11
5.4. On-going procedures 11
6. Application of Article 8(2) of the Orphan Regulation 11
7. Organisational, regulatory and methodological matters 11
7.1. Mandate and organisation of the COMP 11
7.1.1. COMP membership 11

7.1.2. Vote by proxy 12
7.1.3. Strategic Review & Learning meetings 12
7.1.4. Protocol Assistance Working Group (PAWG) 12
7.1.5. COMP Decisions Database 12
7.2. Coordination with EMA Scientific Committees or CMDh-v 12
7.2.1. Recommendation on eligibility to PRIME – report 12
7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups 12
7.3.1. Working Party with Patients' and Consumers' Organisations (PCWP) and Working Party with Healthcare Professionals' Organisations (HCPWP) 12
7.3.2. Upcoming ITF meetings 12
7.4. Cooperation within the EU regulatory network 13
7.4.1. European Commission 13
7.5. Cooperation with International Regulators 13
7.5.1. Food and Drug Administration (FDA) 13
7.5.2. Japanese Pharmaceuticals and Medical Devices Agency (PMDA) 13
7.5.3. Therapeutic Goods Administration (TGA), Australia 13
7.5.4. Health Canada 13
7.6. Contacts of the COMP with external parties and interaction with the Interested Parties to the Committee 13
7.7. COMP work plan 13
7.8. Planning and reporting 13
7.8.1. List of all applications submitted/expected and the COMP rapporteurship distribution of valid applications submitted in 2023 13
7.8.2. Overview of orphan marketing authorisations/applications 13
8. Any other business 13
8.1. Update on progress on Patient Experience Data (PED) 13
8.2. EMA business pipeline activity 14
8.3. Follow up on public summary of opinion on orphan designation 14
9. Explanatory notes 14

1. Introduction

1.1. Welcome and declarations of interest of members and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the COMP plenary session to be held 05-07 September 2023. See September 2023 COMP minutes (to be published post October 2023 COMP meeting).

1.2. Adoption of agenda

COMP agenda for 05-07 September 2023.

1.3. Adoption of the minutes

COMP minutes for 11-13 July 2023.

2. Applications for orphan medicinal product designation

2.1. For opinion

2.1.1. - EMA/OD/0000142116

Treatment of amyotrophic lateral sclerosis

Action: For information

Note: Withdrawal request received on 21 July 2023.

2.1.2. - EMA/OD/0000140986

Treatment of Duchenne muscular dystrophy

Action: For adoption, Oral explanation to be held on 05 September 2023 at 14:00

2.1.3. - EMA/OD/0000124476

Treatment of Duchenne muscular dystrophy

Action: For information

Note: Withdrawal request received on 4 August 2023.

2.1.4. - EMA/OD/0000128649

Treatment of transthyretin-mediated amyloidosis

Action: For adoption, Oral explanation to be held on 05 September 2023 at 17:15

2.1.5. - EMA/OD/0000135016

Treatment of diffuse large B-cell lymphoma

Action: For information

Note: Withdrawal request received on 1 August 2023.

2.1.6. - EMA/OD/0000122901

Treatment of thalassaemia intermedia and major

Action: For adoption, Oral explanation to be held on 06 September 2023 at 12:00

2.1.7. - EMA/OD/0000140879

Treatment of limb-girdle muscular dystrophy (LGMD)

Action: For adoption, Oral explanation to be held on 06 September 2023 at 14:15

2.1.8. - EMA/OD/0000140620

Treatment of glioma

Action: For adoption, Oral explanation to be held on 06 September 2023 at 15:30

2.1.9. - EMA/OD/0000133480

Treatment of Stargardt's disease

Action: For adoption, Oral explanation to be held on 06 September 2023 at 17:00

2.1.10. - EMA/OD/0000138974

Treatment of pancreatic cancer

Action: For adoption, Oral explanation to be held on 07 September 2023 at 09:00

2.1.11. - EMA/OD/0000139967

Treatment of Guillain-Barre syndrome

Action: For adoption, Oral explanation to be held on 07 September 2023 at 10:45

2.1.12. - EMA/OD/0000141035

Treatment of amyotrophic lateral sclerosis (ALS)

Action: For adoption, Oral explanation to be held on 07 September 2023 at 12:00

2.1.13. - EMA/OD/0000138272

Treatment of hypothalamic obesity

Action: For adoption, Oral explanation to be held on 07 September 2023 at 14:00

2.1.14. - EMA/OD/0000137651

Treatment of Smith-Magenis syndrome

Action: For adoption, Oral explanation to be held on 07 September 2023 at 15:30

2.2. For discussion / preparation for an opinion

2.2.1. - EMA/OD/0000128462

Treatment of Alport syndrome

Action: For discussion/adoption

2.2.2. - EMA/OD/0000128771

Treatment of progressive supranuclear palsy

Action: For discussion/adoption

2.2.3. - EMA/OD/0000131662

Treatment of pancreatic cancer

Action: For discussion/adoption

2.2.4. - EMA/OD/0000135459

Treatment of Leigh syndrome

Action: For discussion/adoption

2.2.5. - EMA/OD/0000137539

Treatment of narcolepsy

Action: For discussion/adoption

2.2.6. - EMA/OD/0000139099

Treatment of pancreatic cancer

Action: For discussion/adoption

2.2.7. - EMA/OD/0000139511

Treatment of cutaneous T-cell lymphoma

Action: For discussion/adoption

2.2.8. - EMA/OD/0000140934

Treatment of pulmonary arterial hypertension

Action: For discussion/adoption

2.2.9. - EMA/OD/0000142438

Treatment of Olmsted syndrome

Action: For discussion/adoption

2.2.10. - EMA/OD/0000142531

Treatment of lymphatic malformations

Action: For discussion/adoption

2.2.11. - EMA/OD/0000143040

Treatment of STXBP1 developmental and epileptic encephalopathy

Action: For discussion/adoption

2.2.12. - EMA/OD/0000143251

Treatment of Prader-Willi syndrome

Action: For discussion/adoption

2.2.13. - EMA/OD/0000143825

Treatment of Niemann-Pick disease, type C

Action: For discussion/adoption

2.2.14. - EMA/OD/0000143999

Treatment of ovarian cancer

Action: For discussion/adoption

2.2.15. - EMA/OD/0000144104

Treatment of myelofibrosis

Action: For discussion/adoption

2.2.16. - EMA/OD/0000144182

Treatment of infantile neuroaxonal dystrophy

Action: For discussion/adoption

2.2.17. - EMA/OD/0000144198

Treatment of narcolepsy

Action: For discussion/adoption

2.2.18. - EMA/OD/0000144261

Treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia

Action: For discussion/adoption

2.3. Revision of the COMP opinions

None

2.4. Amendment of existing orphan designations

None

2.5. Appeal

None

2.6. Nominations

2.6.1. New applications for orphan medicinal product designation - Appointment of COMP rapporteurs

Action: For adoption

Document(s) tabled:
OMPD applications - appointment of rapporteurs at the 05-07 September 2023 COMP meeting

2.7. Evaluation on-going

11 applications for orphan designation will not be discussed as evaluation is ongoing.

Action: For information

3. Requests for protocol assistance with significant benefit question

3.1. Ongoing procedures

3.1.1. -

Treatment of spinal cord injury

Action: For adoption

3.1.2. -

Treatment of malignant mesothelioma

Action: For adoption

4. Review of orphan designation for orphan medicinal products at time of initial marketing authorisation

4.1. Orphan designated products for which CHMP opinions have been adopted

None

4.2. Orphan designated products for discussion prior to adoption of CHMP opinion

4.2.1. - quizartinib - EMEA/H/C/005910/0000, EU/3/09/622, EMA/OD/0000134652

Daiichi Sankyo Europe GmbH; Treatment of acute myeloid leukaemia

Action: For adoption, Oral explanation to be held on 05 September 2023 at 12:00

4.2.2. - zilucoplan - EMEA/H/C/005450/0000, EU/3/22/2650, EMA/OD/0000120845

UCB Pharma S.A.; Treatment of myasthenia gravis

Action: For discussion/adoption

4.2.3. – teriparatide - EMEA/H/C/005934, EU/3/20/2350, EMA/OD/0000140073

Ascendis Pharma Bone Diseases A/S; Treatment of hypoparathyroidism

Action: For discussion/adoption

4.3. Appeal

4.3.1. Jaypirca - pirtobrutinib - EMEA/H/C/005863, EU/3/21/2450,

Eli Lilly Nederland B.V.; Treatment of mantle cell lymphoma

Action: For adoption, Oral explanation to be held on 05 September 2023 at 15:30

4.4. On-going procedures

Action: For information

Document(s) tabled:
Review of orphan designation for OMP for MA - On-going procedures

4.5. Orphan Maintenance Reports

Action: For information

5. Review of orphan designation for authorised orphan medicinal products at time marketing authorisation extension

5.1. After adoption of CHMP opinion

None

5.2. Prior to adoption of CHMP opinion

5.2.1. Adcetris - brentuximab vedotin - EMEA/H/C/002455/II/0109, EU/3/08/595, EMA/OD/0000146788

Takeda Pharma A/S; Treatment of peripheral T-cell lymphoma

CHMPRapporteur: Johann Lodewijk Hillege; CHMP Co-Rapporteur: Jan Mueller-Berghaus

Action: For discussion/adoption

5.2.2. Adcetris - brentuximab vedotin - EMEA/H/C/002455/II/0107, EU/3/08/596, EMA/OD/0000136638

Takeda Pharma A/S; Treatment of Hodgkin lymphoma

CHMP Rapporteur: Johann Lodewijk Hillege; CHMP Co-Rapporteur: Jan Mueller-Berghaus

Action: For discussion/adoption

5.3. Appeal

None

5.4. On-going procedures

Action: For information

Document(s) tabled:

Review of orphan designation for OMP for MA extension - On-going procedures

6. Application of Article 8(2) of the Orphan Regulation

None

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the COMP

7.1.1. COMP membership

Action: For information

7.1.2. Vote by proxy

Action: For information

7.1.3. Strategic Review & Learning meetings

Joint COMP-PDCO SRLM under the Spanish Presidency of the Council of the EU to be held F-2-F on 17-18 October 2023 in Madrid, Spain

Action: For information

7.1.4. Protocol Assistance Working Group (PAWG)

Proposed meeting time on 01 September 2023 at 11:15

Document tabled:

PAWG draft agenda for 01 September 2023 meeting

Action: For discussion/adoption

7.1.5. COMP Decisions Database

Action: For discussion

7.2. Coordination with EMA Scientific Committees or CMDh-v

7.2.1. Recommendation on eligibility to PRIME – report

PRIME eligibility requests - list of adopted outcomes July 2023

Action: For information

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.3.1. Working Party with Patients' and Consumers' Organisations (PCWP) and Working Party with Healthcare Professionals' Organisations (HCPWP)

Action: For information

Document(s) tabled:

Meeting Summary PCWP HCPWP 27 and 28 June 2023

Draft Agenda - PCWP-HCPWP Joint meeting - 19 & 20 September 2023

7.3.2. Upcoming ITF meetings

Action: For discussion

Upcoming ITF meetings

7.4. Cooperation within the EU regulatory network

7.4.1. European Commission

None

7.5. Cooperation with International Regulators

7.5.1. Food and Drug Administration (FDA)

None

7.5.2. Japanese Pharmaceuticals and Medical Devices Agency (PMDA)

None

7.5.3. Therapeutic Goods Administration (TGA), Australia

None

7.5.4. Health Canada

None

7.6. Contacts of the COMP with external parties and interaction with the Interested Parties to the Committee

None

7.7. COMP work plan

None

7.8. Planning and reporting

7.8.1. List of all applications submitted/expected and the COMP rapporteurship distribution of valid applications submitted in 2023

Action: For information

7.8.2. Overview of orphan marketing authorisations/applications

Action: For information

8. Any other business

8.1. Update on progress on Patient Experience Data (PED)

Action: For discussion

8.2. EMA business pipeline activity

Action: For information

Document tabled:

Q3-2023 Update of the Business Pipeline report for the human scientific committees

8.3. Follow up on public summary of opinion on orphan designation

Action: For discussion

9. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the COMP agenda and should be read in conjunction with the agenda or the minutes.

Abbreviations / Acronyms

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

EC: European Commission

OD: Orphan Designation

PA: Protocol Assistance

PDCO: Paediatric Committee

PRAC: Pharmacovigilance and Risk Assessment Committee

SA: Scientific Advice

SAWP: Scientific Advice Working Party

Orphan Designation *(section 2 Applications for orphan medicinal product designation)*

The orphan designation is the appellation given to certain medicinal products under development that are intended to diagnose, prevent or treat rare conditions when they meet a pre-defined set of criteria foreseen in the legislation. Medicinal products which get the orphan status benefit from several incentives (fee reductions for regulatory procedures (including protocol assistance), national incentives for research and development, 10-year market exclusivity) aiming at stimulating the development and availability of treatments for patients suffering from rare diseases.

Orphan Designations are granted by Decisions of the European Commission based on opinions from the COMP. Orphan designated medicinal products are entered in the Community Register of Orphan Medicinal Products.

Protocol Assistance *(section 3 Requests for protocol assistance with significant benefit question)*

The protocol assistance is the help provided by the Agency to the sponsor of an orphan medicinal product, on the conduct of the various tests and trials necessary to demonstrate

the quality, safety and efficacy of the medicinal product in view of the submission of an application for marketing authorisation.

Sponsor

Any legal or physical person, established in the Community, seeking to obtain or having obtained the designation of a medicinal product as an orphan medicinal product.

Maintenance of Orphan Designation *(section 4 Review of orphan designation for orphan medicinal products for marketing authorisation).*

At the time of marketing authorisation, the COMP will check if all criteria for orphan designation are still met. The designated orphan medicinal product should be removed from the Community Register of Orphan Medicinal Products if it is established that the criteria laid down in the legislation are no longer met.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/